Get the Stockscreener App
1.38
3.50%
-0.05
After Hours:
1.38
Neumora Therapeutics Inc Stock (NMRA) Latest News
Lowey Dannenberg Notifies Neumora Therapeutics, Inc. - GlobeNewswire
NMRA CLASS ACTION FILED: Kessler Topaz Meltzer & Check, LLP Reminds Investorsa Securities Fraud Class Action Lawsuit Has Been Filed Against Neumora Therapeutics, Inc. (NMRA) | FinancialContent - Financial Content
NMRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Neumora Therapeutics, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - Markets Insider
2025-03-12 | Neumora Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your RightsNMRA | NDAQ:NMRA | Press Release - Stockhouse Publishing
2025-03-11 | Investors who lost money on Neumora Therapeutics, Inc.(NMRA) should contact Levi & Korsinsky about pending Class ActionNMRA | NDAQ:NMRA | Press Release - Stockhouse Publishing
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Neumora Therapeutics, Inc of Class Action Lawsuit and Upcoming DeadlinesNMRA - PR Newswire
NASDAQ: NMRA Lawsuit Alert: Investors with substantial Losses from shares of Neumora Therapeutics, Inc. (NASDAQ: NMRA) should contact the Shareholders Foundation - PR Newswire
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Neumora Therapeutics - GlobeNewswire
NMRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Neumora Therapeutics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - Markets Insider
Equities Analysts Issue Forecasts for NMRA Q1 Earnings - MarketBeat
Neumora Therapeutics (NASDAQ:NMRA) Downgraded to Market Perform Rating by William Blair - Defense World
Neumora cut to Hold at Stifel after J&J’s VENTURA exit - MSN
NMRA LAWSUIT ALERT: Levi & Korsinsky Notifies Neumora Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire
2025-03-10 | Shareholders that Lost Money on Neumora Therapeutics, Inc. (NMRA) Urged to Join Class ActionContact Levi & Korsinsky to Learn More | NDAQ:NMRA | Press Release - Stockhouse Publishing
Levi & Korsinsky Notifies Neumora Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineNMRA - ACCESS Newswire
2025-03-10 | NMRA LAWSUIT ALERT: Levi & Korsinsky Notifies Neumora Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline | NDAQ:NMRA | Press Release - Stockhouse Publishing
Neumora Therapeutics, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationNMRA - ACCESS Newswire
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Neumora Therapeutics - StreetInsider.com
Shareholders of Neumora Therapeutics, Inc. Should Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your RightsNMRA - ACCESS Newswire
William Blair Downgrades Neumora Therapeutics (NASDAQ:NMRA) to Market Perform - MarketBeat
NMRA STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Neumora Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - Markets Insider
Neumora Therapeutics (NASDAQ:NMRA) Downgraded by William Blair to Market Perform - MarketBeat
William Blair Downgrades Neumora Therapeutics to Market Perform From Outperform -March 10, 2025 at 07:50 am EDT - Marketscreener.com
NEUMORA THERAPEUTICS, INC. (NASDAQ: NMRA) DEADLINE ALERT: - GlobeNewswire
NEUMORA THERAPEUTICS, INC. (NASDAQ: NMRA) DEADLINE ALERT: Bernstein Liebhard LLP Reminds ... - The Bakersfield Californian
Neumora Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before April 7, 2025 to Discuss Your RightsNMRA - Morningstar
HC Wainwright Issues Positive Estimate for NMRA Earnings - MarketBeat
Head-To-Head Analysis: Cidara Therapeutics (NASDAQ:CDTX) vs. Neumora Therapeutics (NASDAQ:NMRA) - Defense World
What is William Blair's Forecast for NMRA Q1 Earnings? - MarketBeat
2025-03-09 | Shareholders of Neumora Therapeutics, Inc. Should Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your RightsNMRA | NDAQ:NMRA | Press Release - Stockhouse Publishing
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Neumora Therapeutics, Inc. Investors to Secure ... - Bluefield Daily Telegraph
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Neumora - GlobeNewswire
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Neumora Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – NMRA - GlobeNewswire Inc.
Levi & Korsinsky Reminds Neumora Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 7, 2025NMRA - ACCESS Newswire
Contact Levi & Korsinsky by April 7, 2025 Deadline to Join Class Action Against Neumora Therapeutics, Inc.(NMRA) - ACCESS Newswire
NMRA STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Neumora Therapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - Markets Insider
2025-03-09 | NMRA STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Neumora Therapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! | NDAQ:NMRA | Press Release - Stockhouse Publishing
Neumora Therapeutics (NASDAQ:NMRA) Rating Lowered to “Hold” at Stifel Nicolaus - Defense World
Royal Bank of Canada Reiterates "Sector Perform" Rating for Neumora Therapeutics (NASDAQ:NMRA) - MarketBeat
Neumora Therapeutics (NASDAQ:NMRA) Downgraded to Neutral Rating by Guggenheim - MarketBeat
Neumora Therapeutics (NASDAQ:NMRA) Cut to Hold at Stifel Nicolaus - MarketBeat
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Neumora Therapeutics - GlobeNewswire
Neumora Therapeutics (NASDAQ:NMRA) Given Buy Rating at Needham & Company LLC - MarketBeat
NMRA stock touches 52-week low at $1.32 amid market challenges - Investing.com Australia
Levi & Korsinsky Notifies Neumora Therapeutics, Inc. - GlobeNewswire
NMRA: Riding the Market Waves of Growth and Decline in 2023 - The InvestChronicle
Neumora falls as J&J's setback triggers concerns over depression drug - TradingView
Guggenheim cuts Neumora Therapeutics stock rating to neutral By Investing.com - Investing.com Australia
Guggenheim cuts Neumora Therapeutics stock rating to neutral - Investing.com
Douglas Tsao Recommends ‘Buy’ for Neumora Therapeutics Due to Navacaprant’s Market Potential and Differentiated Pharmacology - TipRanks
NMRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Stockholders of Neumora Therapeutics, Inc. to Contact the Firm Today! - Markets Insider
Neumora Therapeutics downgraded to Neutral from Buy at Guggenheim - TipRanks
Stifel Downgrades Neumora Therapeutics to Hold From Buy, Adjusts Price Target to $2 From $6 - Marketscreener.com
Investors who lost money on Neumora Therapeutics, Inc.(NMRA) should contact Levi & Korsinsky about pending Class ActionNMRA - PR Newswire
Cautious Hold Rating on Neumora Therapeutics Amid Efficacy Concerns and Clinical Trial Setbacks - TipRanks
Neumora Therapeutics’ (NMRA) Buy Rating Reiterated at Needham & Company LLC - Defense World
HC Wainwright Has Optimistic Outlook of NMRA Q2 Earnings - Defense World
Q1 EPS Forecast for Neumora Therapeutics Boosted by Analyst - Defense World
Stifel cuts Neumora Therapeutics stock rating to hold - Investing.com
HC Wainwright Issues Pessimistic Forecast for Neumora Therapeutics (NASDAQ:NMRA) Stock Price - MarketBeat
Neumora Therapeutics (NASDAQ:NMRA) Releases Quarterly Earnings Results, Beats Expectations By $0.09 EPS - MarketBeat
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Neumora Therapeutics, Inc. Investors to Secure - Bluefield Daily Telegraph
J&J to stop studies of depression drug due to low effectiveness - Reuters
NMRA Investors are Suing Neumora Therapeutics, Inc.; Contact Robbins LLP for More Information - The National Law Review
3.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):